Novo Nordisk Plans Authorized Generic Insulins for Early 2020
September 12th 2019
By The Center for Biosimilars Staff
ArticleInsulin maker Novo Nordisk has announced that, in January of 2020, it will launch authorized generics of its NovoLog (insulin aspart) and NovoLog Mix (insulin aspart protamine and insulin aspart) products. Notably, the authorized generics will become available before the March 2020 transition of insulins to regulation as biologics and biosimilars rather than drugs and generics.